A Phase Ib, Multicentre, Double Blind, Randomized, Two-part Study, First Part Multiple Rising Dose and Second Part Two-way Cross-over, to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of BI 443651 Compared to Placebo Via Respimat® in Healthy Volunteers and CF Subjects.

Trial Profile

A Phase Ib, Multicentre, Double Blind, Randomized, Two-part Study, First Part Multiple Rising Dose and Second Part Two-way Cross-over, to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of BI 443651 Compared to Placebo Via Respimat® in Healthy Volunteers and CF Subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs BI 443651 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 30 Dec 2017 to 28 Feb 2018.
    • 11 Jul 2017 Planned End Date changed from 1 Nov 2017 to 30 Dec 2017.
    • 11 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 30 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top